EGFR and non-small cell lung carcinoma: In the present study, we suggested an additional approach, based on the ability of the HDACis vorinostat and VPA to enhance the A3 anti-tumor activity, and provided evidences, for the first time, that the HDACi/A3 combination represents a viable strategy that warrants clinical investigation for the treatment of NSCLC patients, independently of EGFR status or other molecular features.